2183 LONG-TERM OUTCOME FOLLOWING THULIUM VAPOENUCLEATION OF THE PROSTATE

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy and New Technology (III)1 Apr 20132183 LONG-TERM OUTCOME FOLLOWING THULIUM VAPOENUCLEATION OF THE PROSTATE Christopher Netsch, Alexander Engbert, Thorsten Bach, and Andreas Gross Christopher NetschChristopher Netsch Hamburg, Germany More articles by this author , Alexander EngbertAlexander Engbert Hamburg, Germany More articles by this author , Thorsten BachThorsten Bach Hamburg, Germany More articles by this author , and Andreas GrossAndreas Gross Hamburg, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2092AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES A prospective study to assess the safety, efficacy, and long-term durability of Thulium VapoEnucleation of the prostate (ThuVEP) for the treatment of symptomatic benign prostatic obstruction (BPO). METHODS One-hundred twenty-four patients underwent ThuVEP between January 2007 and July 2008 at our institution. Patient demographics, perioperative complications, and long-term follow-up data were analyzed. RESULTS Mean age was 70.62±7.95 yrs. Mean prostate volume was 62.3±26.56 cc. Mean operation time was 80.72±28.78 and the enucleation time 32.83±10.04 min, whilst resected tissue weighted 32.97±22.22 gm. Mean catheter time and hospital stay was 2.12±0.87 and 5.5±2.25 days, respectively. Nine (7.3%) patients required a second-look operation in the immediate postoperative course (failed morcellation n=2, clot retention n=3, residual tissue at the apex of the prostate n=4). Two patients needed blood transfusions (1.6%) postoperatively. At 12-month follow-up, international prostate symptom score (IPSS), quality of life (QoL), maximum urinary flow rate (Qmax), postvoid residual urine (PVR), and prostate-specific antigen (PSA) improved significantly in comparison to preoperative assessment (p<0.001) and continued to do so during subsequent follow-up. At 48-month follow-up, mean Qmax (8.9 vs. 22 ml/s), PVR (126.43 vs. 47.6 ml), IPSS (18.67 vs. 4.8) and QoL (4 vs. 1.33) improved significantly compared with baseline (p<0.001). Bladder-neck contractures and urethral strictures each developed in 1.6% and 0.8% of the patients. None of the patients were re-treated during follow-up for recurrent prostatic tissue. CONCLUSIONS ThuVEP is a safe, efficacious, and durable procedure for the treatment of symptomatic BPO. The incidence of late complications with ThuVEP was very low. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e895 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Christopher Netsch Hamburg, Germany More articles by this author Alexander Engbert Hamburg, Germany More articles by this author Thorsten Bach Hamburg, Germany More articles by this author Andreas Gross Hamburg, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...